Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Core Insights - Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system conditions [2] - The company plans to host a conference call and webcast on November 13, 2025, to discuss its financial results for Q3 2025 and recent business progress [1] Company Overview - Relmada's lead candidates, NDV-01 and sepranolone, are in mid-stage clinical development and aim to address significant unmet medical needs [2] - The company is advancing therapies that could transform treatment options in their targeted areas [2] Conference Call Details - The conference call is scheduled for November 13, 2025, at 4:30 PM ET [1][3] - Participants can access the call via US and international dial-in numbers, and a replay will be available on the company's website [3]